Alzheimer's Disease
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global Alzheimer's disease market intelligence for pharma BD, investors & analysts. Track drug development, clinical trials & regulatory updates.
Showing 1–12 of 16 articles
Quick answer
NovaPharmaNews Alzheimer's Disease hub for FDA covers 16 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease
Eisai's Leqembi Sales Forecast: A Turning Point?
Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD
Bristol Myers' Innovative Approach to Alzheimer's Beyond Amyloid
AC Immune Advances ACI-24 Alzheimer's Trial to Final Cohort, Initiates ACI-19764 Phase 1 Study
AC Immune Initiates Final Cohort in Phase 1b/2 ABATE Trial for Anti-Abeta Alzheimer's Treatment
FDA Breakthrough Therapy Designations: Impact on Neurological Disorder Investments 2026
Breakthrough Therapy Designations Drive Neurological Drug Innovation in US
FDA Approves Synapton: Breakthrough for Severe Alzheimer's Treatment
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.